AB SCIENCE |
Market Closed -
Other stock markets
|
After market 15:59:55 | |||
| 2.21 EUR | -3.07% |
|
2.2 | -0.45% |
| 05-13 | AB Science: European patent granted for masitinib | CF |
| 05-03 | AB Science: upbeat after legal success | CF |
ETFs positioned on AB Science
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 10 M€ | -3.35% | - |
AB Science specializes in research, development, and sales of kinase protein inhibitors (KPI), therapeutic drugs used in treating cancerous tumors, inflammatory and neuro-degenerative diseases in both humans and animals.
Sector
Pharmaceuticals
Calendar
2024-09-29
- Q2 2024 Earnings Release
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.28
EUR
Average target price
6.895
EUR
Spread / Average Target
+202.41%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -37.83% | 127M | |
| +11.98% | 9.08B | |
| -10.76% | 5.06B | |
| +53.60% | 4.85B | |
| +7.56% | 3.85B | |
| +14.09% | 2.37B | |
| -21.42% | 2.36B | |
| +25.03% | 2.27B | |
| -30.36% | 2.22B | |
| -0.50% | 1.64B |
- Stock Market
- Equities
- AB Stock
- Funds and ETFs AB Science